Group 1: Industry Overview - The pet economy in Zhejiang Province aims to exceed 30 billion yuan by 2027 and 50 billion yuan by 2030, establishing itself as a national innovation hub for pet economy and a major producer of pet food and supplies [1] - The pet industry is experiencing rapid growth, with various cities like Suzhou and Wuxi implementing supportive policies to enhance the pet economy [1] - The global OTC pet medicine market is projected to grow from 9.8 billion USD in 2025 to 16.4 billion USD by 2034, with a CAGR of 5.9% [4] Group 2: Company Positioning - Haisheng Pharmaceutical is a key player in the veterinary medicine sector, possessing the longest supply chain for sulfonamide raw materials and a comprehensive product range [2] - The company is actively developing pet raw materials and enhancing existing product quality while expanding production capacity to strengthen its competitive edge [1][2] - Haisheng Pharmaceutical has established three research pipelines for pet raw materials, focusing on improving synthesis processes and increasing product variety [2] Group 3: Financial Performance - In the first three quarters of 2025, Haisheng Pharmaceutical reported revenue of 164 million yuan, a year-on-year increase of 40.89%, and a net profit of 49.05 million yuan, up 47.16% [3] - The company achieved a third-quarter revenue of 62.99 million yuan, reflecting a 38.94% year-on-year growth, with a net profit increase of 89.48% [3] - The significant improvement in cash flow, with a net increase of 1527.50%, indicates enhanced profitability and provides a solid foundation for business expansion [3]
多地加码宠物经济扶持 海昇药业借力兽药积淀开辟宠物药增长新曲线